Skip to content
Screener

Hemab Therapeutics Holdings, Inc. COAG EBITDA

EBITDA at other companies

Ambarella logo
AmbarellaAMBA
-$13.05M+31.7%
PVH logo
PVHPVH
$186.9M+171%
Academy Sports and Outdoors logo
Academy Sports and OutdoorsASO
$105.41M+6.0%
Alumis Inc. logo
Alumis Inc.ALMS
-$97.54M+3.1%
Worthington Enterprises logo
Worthington EnterprisesWOR
$46.1M+40.5%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$107.86M-28.7%

Other financials

Income statement

See full
Operating income-$26.1M-62.4%
Net income-$24.2M-97.8%
EPS (diluted)-$0.80+93.8%

Balance sheet

See full
Cash & equivalents$237.4M—
Total debt$1.0M—
Total equity$454.3M+421%
Total assets$467.8M—

Cash flow

See full
Operating cash flow-$22.6M-47.6%
CapEx$23.0K—
Free cash flow-$22.7M-47.8%

Valuation

See full
Market cap$2.32B+107%
Enterprise value$2.08B—

Returns & leverage

See full
Return on equity-45.7%—
Debt / equity0×—
Current ratio35.8×—

Where this comes from

Calculated from Hemab Therapeutics Holdings, Inc.’s reported figures.

−$26.1Mebit+
$75.0KDepreciation Depletion & Amortization
=-$26M

The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344533

FAQ

What is Hemab Therapeutics Holdings, Inc.'s EBITDA?
Hemab Therapeutics Holdings, Inc. (COAG) reported EBITDA of -$26M in Q2 2026.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Hemab Therapeutics Holdings, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude